Allergan, Inc.

Michelle H Luu

Lon T Spada

James Nienyuan Chang

Hongwen Ma Rivers

Wendy M Blanda

David A Marsh

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.

Processes for making cyclic lipid implants for intraocular use

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

Autoclavable suspensions of cyclosporin A Form 2

The present invention provides an ocular implant of siRNA complexed with a transfection agent such as cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer. The biocompatible polymer includes a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Sustained release siRNA for ocular drug delivery

An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Growing community of inventors

Anaheim, CA, United States of America

Michelle H Luu